Common side effects include problems with vision, joint pain, nausea, headaches, and feeling tired.[4] Other side effects include liver problems and allergic reactions.[4] It is not recommended in people with optic neuritis, significant kidney problems, or under the age of five.[5] Use during pregnancy or breastfeeding has not been found to cause harm.[5][6] In the United States the FDA has raised concerns about eye issues in the baby if used during pregnancy.[4] Ethambutol is believed to work by interfering with the bacteria's metabolism.[4]
(S,S)-(+)-Ethambutol is powerful and selective antitubercular drug. It is a typical example of an old drug that was introduced for clinical use in its unichiral form. Ethambutol contains two constitutionally symmetrical chiral centers in its structure and exists in three stereoisomeric forms, the enantiomeric pair (+)-(S,S)- and (−)-(R,R)-ethambutol, along with the achiral stereoisomer called meso-form. The (+)-(S,S)-enantiomer harbors the antitubercular activity. This enantiomer is 500 and 12 fold more potent than (−)-(R,R)-ethambutol and the meso-form respectively. On the other hand, all the three isomers are equipotent in terms of the major side-effect of the drug, optic neuritis.[9] Toxicity is associated to both dose and duration of treatment. Hence the use of (S,S)-enantiomer greatly improved the risk/benefit balance.[10][11]
Ethambutol is bacteriostatic against actively growing TB bacilli. It works by obstructing the formation of cell wall. Mycolic acids attach to the 5'-hydroxyl groups of D-arabinose residues of arabinogalactan and form mycolyl-arabinogalactan-peptidoglycan complex in the cell wall. It disrupts arabinogalactan synthesis by inhibiting the enzyme arabinosyl transferase. Disruption of the arabinogalactan synthesis inhibits the formation of this complex and leads to increased permeability of the cell wall.[citation needed]
Pharmacokinetics
It is well absorbed from the gastrointestinal tract and well distributed in body tissues and fluids. 50% is excreted unchanged in urine.
References
^ abHamilton R (2015). Tarascon Pocket Pharmacopoeia (Deluxe Lab-Coat ed.). Jones & Bartlett Learning. p. 48. ISBN9781284057560.
^"ethambutol (CHEBI:4877)". Chemical Entities of Biological Interest. UK: European Bioinformatics Institute. 18 August 2010. Main. Archived from the original on 19 July 2014. Retrieved 26 April 2012 – via ebi.ac.uk.
^ abcStuart MC, Kouimtzi M, Hill SR, eds. (2009). WHO Model Formulary 2008. World Health Organization. pp. 136, 138, 588, 603. hdl:10665/44053. ISBN9789241547659.
^Organization WH (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^ abLewis SM, Dirksen SR, Heitkemper MM, Bucher L, Harding M (5 December 2013). Medical-surgical nursing : assessment and management of clinical problems (9th ed.). St. Louis, Missouri. ISBN978-0-323-10089-2. OCLC228373703.{{cite book}}: CS1 maint: location missing publisher (link)
^Tripathi KD (August 2015). Essentials of Medical Pharmacology (Seventh ed.). India: Jaypee Brothers Medical Publishers. p. 769. ISBN978-93-5025-937-5.